Occudo Quantitative Strategies LP acquired a new position in Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 103,408 shares of the company's stock, valued at approximately $1,637,000. Occudo Quantitative Strategies LP owned 0.26% of Keros Therapeutics as of its most recent SEC filing.
A number of other large investors have also recently made changes to their positions in KROS. AlphaQuest LLC boosted its holdings in Keros Therapeutics by 469.0% in the 4th quarter. AlphaQuest LLC now owns 3,596 shares of the company's stock worth $57,000 after buying an additional 2,964 shares during the period. Virtus ETF Advisers LLC lifted its position in shares of Keros Therapeutics by 107.5% in the fourth quarter. Virtus ETF Advisers LLC now owns 3,857 shares of the company's stock valued at $61,000 after acquiring an additional 1,998 shares in the last quarter. KLP Kapitalforvaltning AS bought a new position in shares of Keros Therapeutics in the fourth quarter worth about $90,000. Exchange Traded Concepts LLC bought a new stake in Keros Therapeutics during the 4th quarter valued at approximately $99,000. Finally, CANADA LIFE ASSURANCE Co lifted its holdings in Keros Therapeutics by 207.8% in the 4th quarter. CANADA LIFE ASSURANCE Co now owns 7,371 shares of the company's stock worth $116,000 after purchasing an additional 4,976 shares in the last quarter. 71.56% of the stock is owned by hedge funds and other institutional investors.
Keros Therapeutics Stock Up 0.3%
Shares of NASDAQ KROS traded up $0.04 during trading hours on Friday, hitting $14.07. 633,971 shares of the stock were exchanged, compared to its average volume of 833,904. Keros Therapeutics, Inc. has a 12 month low of $9.12 and a 12 month high of $72.37. The firm has a fifty day moving average price of $12.38 and a 200-day moving average price of $23.44. The company has a market cap of $571.45 million, a PE ratio of -2.70 and a beta of 1.32.
Keros Therapeutics (NASDAQ:KROS - Get Free Report) last released its earnings results on Tuesday, May 6th. The company reported $3.62 EPS for the quarter, topping analysts' consensus estimates of ($0.01) by $3.63. The company had revenue of $211.25 million during the quarter, compared to analysts' expectations of $84.62 million. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. During the same period last year, the business earned ($1.21) EPS. As a group, equities analysts anticipate that Keros Therapeutics, Inc. will post -4.74 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
Several equities analysts have recently commented on the stock. Truist Financial lowered their target price on shares of Keros Therapeutics from $43.00 to $25.00 and set a "buy" rating on the stock in a report on Wednesday, April 9th. Scotiabank decreased their price target on shares of Keros Therapeutics from $41.00 to $26.00 and set a "sector outperform" rating on the stock in a research note on Monday. Wedbush restated a "neutral" rating and set a $15.00 price objective on shares of Keros Therapeutics in a research report on Tuesday, April 1st. Cantor Fitzgerald cut Keros Therapeutics from an "overweight" rating to a "neutral" rating in a report on Tuesday, January 21st. Finally, Oppenheimer dropped their price target on Keros Therapeutics from $63.00 to $23.00 and set an "outperform" rating for the company in a research note on Thursday, January 16th. Six equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $37.00.
Get Our Latest Analysis on KROS
Insider Buying and Selling at Keros Therapeutics
In other Keros Therapeutics news, major shareholder Adar1 Capital Management, Llc purchased 934,258 shares of the firm's stock in a transaction dated Wednesday, April 9th. The shares were purchased at an average cost of $10.13 per share, with a total value of $9,464,033.54. Following the completion of the purchase, the insider now owns 4,392,737 shares in the company, valued at approximately $44,498,425.81. This represents a 27.01% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this link. 22.90% of the stock is owned by corporate insiders.
About Keros Therapeutics
(
Free Report)
Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.
Further Reading
Before you consider Keros Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Keros Therapeutics wasn't on the list.
While Keros Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
